Skip to main content
. Author manuscript; available in PMC: 2023 Jul 19.
Published in final edited form as: Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095

Figure 2. SHP099 inhibits MEK/ERK pathway in neuroblastoma cell lines.

Figure 2.

(A) Immunoblot of NB cell lines indicated treated with SHP099 (5 μM) for 6 and 24 h, respectively, or untreated (No Rx) and assessed with the indicated antibodies. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. SHP099-sensitive lines are depicted in red font, and SHP099-resistant lines are depicted in black font.

(B) Immunoblot of NB cell lines (ALK WT, ALK F1174L mut) treated with SHP099 (5 μM) ortrametinib (1 μM) for 24 h or untreated control (No Rx) were assessed with the indicated antibodies.

See also Figures S4-S6.